Is high-risk BCR really mHSPC?? Live webinar replay
We recently hosted another live webinar for our Gold Partners, Mundipharma, this time asking the question, "Is high-risk BCR actually metastatic prostate cancer??". It's a reasonable question! This podcast was anchored from the GU Cast studio in Melbourne by usual hosts, Renu Eapen and Declan Murphy, joined in person by Andrew Loblaw, radiation oncologist from Toronto, and online by medical oncologist Jeff Goh in Brisbane.Best enjoyed on our YouTube channel if you want to check out the slides. Runsheet:Is high-risk biochemical recurrence already metastatic prostate cancer?Declan MurphyIs the management of high-risk BCR and mHSPC now the same? Jeffrey GohProstate radiotherapy is the real triplet therapy; plus when should we use SBRT? Andrew LoblawQ&A and case discussionsThis webinar was organised by our Gold Partners, Mundipharma, who also support GU Cast as Gold Partners through an unrestricted educational grant.
-------- Â
1:30:59
--------
1:30:59
SABR and LuPSMA for mHSPC? Let's talk LUNAR
Dr Amar Kishan (Radiation Oncologist, UCLA, USA), made lots of headlines recently when he presented data from the phase II randomised LUNAR trial of SABR +/- LuPSMA in patients with oligometastatic prostate cancer. So we were very happy when he turned up in Melbourne recently and popped into the GU Cast studio for a chat. We discuss metastasis-directed therapy and bring up our favourite Pokemet analogies, and ask should we not just be offering these patients and ADT/ARPI doublet?! Regular hosts Declan Murphy and Renu Eapen, also joined by Prof Wee Ong, Radiation Oncologist at Alfred Health in Melbourne. This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson. Even better on our YouTube channelÂ
-------- Â
34:24
--------
34:24
Let's do some UroTraining! WIth Gonzalo Vitagliano & Maxi Ringa
Fun today as we go to the OR to test drive some high-fidelity radical prostatectomy models and chat with the team behind UroTrainer - world leaders in urologic simulation. Urologists Gonzalo Vitagliano and Maxi Ringa join us from Buenos Aries to tell us all about UroTrainer and why they have worked hard to create these beautiful models for trainees to improve their skills in minimally-invasive prostate and kidney surgery. They also tell us about their range of hands-on courses around the world and their innovative remote laparoscopic training courses so trainees can do training from home while being proctored remotely. Declan Murphy also joins senior trainees Christa Babst and Eoin Dinneen in the OR as they test the construct validity of three prostatectomy models using a da Vinci surgical robot. These are beautiful simulation models, best in the business in our view! Well done to the UroTrainer team and keep up the good work.Thsi one best appreciated on our YouTube channel Links:Urotrainer websiteÂ
-------- Â
24:58
--------
24:58
In London for #ERUS25 - a festival of robotic surgery!
One of our favourite meetings of the year! The EAU Robotic Urology Section (ERUS) Annual Meeting took place in London recently and was an unashamed exposition of robotic surgery in urology. More than 30 amazing live surgeries, and some fantastic plenary sessions focussing on technical aspects. Multiple different robots, and spectacular telesurgery with surgeons sitting in London, performing robotic surgery up to 8000km away! Join Host Declan Murphy to get a flavour of this year's meeting, and to hear from many of the surgeons involved.With thanks to our Silver Partners, Device Technologies. This one best appreciated on our YouTube channel.
-------- Â
50:17
--------
50:17
Journal club #3 | ERSPC and NIAGARA
Episode 3 of our monthly GU Cast Journal Club and today we focus on one classic paper in Urology, and one from recent times - the ERSPC randomised trial of screening in prostate cancer, and the NIAGARA trial evaluating peri-operative immunotherapy in muscle-invasive bladder cancer. We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. Watch out for Declan getting all misty-eyed recalling when the ERSPC was published back in 2009 (the rest of the team are too young to remember this)! Links to papers below:1. Screening and Prostate-Cancer Mortality in a Randomized European Study NEJM 20092. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer NEJM 2024GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant.Even better on our YouTube channelAbout GU Cast Journal Club:Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.
A urology podcast, focussing on prostate cancer, kidney cancer, bladder cancer, testis and penile cancer. Join Professor Declan Murphy and Dr Renu Eapen from Peter MacCallum Cancer Centre in Melbourne for this regular dive into the world of genitourinary (GU) Oncology and Urology. Regular guests from all over the world, from every walk of life. Find out more gucast.org
Ireland